Compass Pathways plc has announced a strategic collaboration with Radial Health, Inc., a national network of interventional psychiatry practices in the United States. The partnership aims to innovate the patient experience and inform potential delivery models for COMP360, Compass’s investigational psilocybin treatment for mental health conditions, if approved by the FDA. This agreement with Radial marks Compass’s seventh collaboration, broadening its efforts to explore scalable care delivery models across various healthcare settings. The collaboration is expected to provide valuable insights into how COMP360 treatment could be integrated into mental health care in the U.S.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20260106107839) on January 06, 2026, and is solely responsible for the information contained therein.